Bionano Genomics, Inc.
BNGONasdaq
$1.15
↓ -1.7%Jul 17 close · end-of-day
Price
1Y↓ -66.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$12.6M
Enterprise Value
-$1.8M
P/E
—
P/S
0.4
P/B
0.3
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$28.7M
Net Income (TTM)
-$31.6M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-114.0%
Net Margin
-109.9%
ROE
-84.3%
ROIC
-112.3%
Debt / Equity
—
Net Cash
$14.4M
Return 1Y
-66.2%
Company profile
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping. NxClinical offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics.
- CEO
- Robert E. Holmlin
- Sector
- Manufacturing
- Industry
- Measuring And Control Equipment
- Employees
- 300
- Headquarters
- California
- Website
- bionanogenomics.com
Management & directors
- Adamchak MarkPrincipal Accounting Officer
- Borodkin MarkCHIEF OPERATING OFFICER
- Chaubey AlkaCHIEF MEDICAL OFFICER
- Dixon Jonathan V.GENERAL COUNSEL
- Holmlin R. ErikPRESIDENT AND CEO
Roles derived from SEC Form 4 filings.
Earnings
BNGO Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$6.7M↑ +3.6%
Diluted EPS-$0.76↓ -33.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $8.5M | $18.0M | $27.8M | $36.1M | $30.8M | $28.5M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$38.6M | -$77.1M | -$131.7M | -$215.2M | -$104.0M | -$33.3M |
| Net income | -$41.1M | -$72.4M | -$132.6M | -$232.5M | -$112.0M | -$26.4M |
| Diluted EPS | — | -$0.26 | -$4.58 | -$408.60 | -$88.13 | -$4.85 |
| Operating cash flow | -$38.3M | -$71.9M | -$124.8M | -$125.2M | -$68.9M | -$16.3M |
| Free cash flow | -$38.3M | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -453.4% | -428.8% | -473.7% | -596.0% | -337.9% | -116.9% |
| Net margin | -483.4% | -402.8% | -476.9% | -643.7% | -364.0% | -92.6% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.8M | $6.1M | $8.2M | $6.5M | $6.7M | $7.4M | $8.0M | $6.7M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$17.0M | -$43.9M | -$11.9M | -$8.5M | -$7.8M | -$8.5M | -$8.5M | -$7.9M |
| Net income | -$16.2M | -$44.2M | -$20.1M | -$3.1M | -$6.9M | -$8.5M | -$7.9M | -$8.3M |
| Diluted EPS | -$14.41 | -$30.92 | -$7.05 | -$1.15 | -$1.99 | -$1.59 | -$0.12 | -$0.76 |
| Operating cash flow | -$21.0M | -$13.3M | -$6.5M | -$2.8M | -$3.5M | -$5.9M | -$4.2M | -$5.7M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -219.0% | -722.9% | -146.3% | -131.1% | -115.8% | -115.9% | -107.4% | -118.1% |
| Net margin | -208.8% | -728.6% | -246.5% | -48.0% | -101.8% | -115.4% | -99.8% | -124.2% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-03 | Borodkin Mark· CHIEF OPERATING OFFICER | Tax withholding | 27 | $1.30 | $35.10 | filing |
| 2026-06-03 | Dixon Jonathan V.· GENERAL COUNSEL | Tax withholding | 24 | $1.30 | $31.20 | filing |
| 2026-06-03 | Chaubey Alka· CHIEF MEDICAL OFFICER | Tax withholding | 24 | $1.30 | $31.20 | filing |
| 2026-06-03 | Adamchak Mark· Principal Accounting Officer | Tax withholding | 7 | $1.30 | $9.10 | filing |
| 2026-02-17 | Holmlin R. Erik· PRESIDENT AND CEO | Tax withholding | 51 | $1.10 | $56.10 | filing |
| 2026-02-17 | Borodkin Mark· CHIEF OPERATING OFFICER | Tax withholding | 20 | $1.10 | $22.00 | filing |
| 2026-02-17 | Chaubey Alka· CHIEF MEDICAL OFFICER | Tax withholding | 18 | $1.10 | $19.80 | filing |
| 2026-02-17 | Dixon Jonathan V.· GENERAL COUNSEL | Tax withholding | 6 | $1.10 | $6.60 | filing |
| 2026-02-17 | Adamchak Mark· Principal Accounting Officer | Tax withholding | 3 | $1.10 | $3.30 | filing |
| 2025-09-11 | Borodkin Mark· Chief Operating Officer | Tax withholding | 59 | $4.06 | $239.54 | filing |
| 2025-09-11 | Borodkin Mark· Chief Operating Officer | Tax withholding | 59 | $4.06 | $239.54 | filing |
| 2025-09-11 | Chaubey Alka· Chief Medical Officer | Tax withholding | 51 | $4.06 | $207.06 | filing |
Latest 12 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.